Abstract
Misfolded protein amyloid-beta protein (Aβ) and tau protein are two high hallmarks of Alzheimer’s disease (AD), representing significant targets in treating AD. Researches on mechanisms of the two proteins inducing neuron dysfunctions provide therapeutic strategies of AD, including inhibition of Aβ production and aggregation, acceleration of Aβ clearance as well as reduction of tau hyperphosphorylation. Proteoglycans (PGs) consist of a core protein and glycosaminoglycans (GAGs) chains, with enormous structural diversity due to variation in the core protein, the number of GAGs chains as well as extent and position of sulfation. Considerable evidences have indicated that PGs and GAGs play important roles in Aβ and tau processing. Numbers of GAGs and analogues have potential therapeutic function in AD. In this Review, we focus on the relationship of PGs and GAGs with misfolded proteins in AD and their potential therapeutic implications.
Keywords: Alzheimer’s disease, amyloid-beta protein, glycosaminoglycans, proteoglycans, tau protein.
Protein & Peptide Letters
Title:Proteoglycans and Glycosaminoglycans in Misfolded Proteins Formation in Alzheimer's Disease
Volume: 21 Issue: 10
Author(s): Peipei Wang and Kan Ding
Affiliation:
Keywords: Alzheimer’s disease, amyloid-beta protein, glycosaminoglycans, proteoglycans, tau protein.
Abstract: Misfolded protein amyloid-beta protein (Aβ) and tau protein are two high hallmarks of Alzheimer’s disease (AD), representing significant targets in treating AD. Researches on mechanisms of the two proteins inducing neuron dysfunctions provide therapeutic strategies of AD, including inhibition of Aβ production and aggregation, acceleration of Aβ clearance as well as reduction of tau hyperphosphorylation. Proteoglycans (PGs) consist of a core protein and glycosaminoglycans (GAGs) chains, with enormous structural diversity due to variation in the core protein, the number of GAGs chains as well as extent and position of sulfation. Considerable evidences have indicated that PGs and GAGs play important roles in Aβ and tau processing. Numbers of GAGs and analogues have potential therapeutic function in AD. In this Review, we focus on the relationship of PGs and GAGs with misfolded proteins in AD and their potential therapeutic implications.
Export Options
About this article
Cite this article as:
Wang Peipei and Ding Kan, Proteoglycans and Glycosaminoglycans in Misfolded Proteins Formation in Alzheimer's Disease, Protein & Peptide Letters 2014; 21 (10) . https://dx.doi.org/10.2174/0929866521666140626095145
DOI https://dx.doi.org/10.2174/0929866521666140626095145 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Morpho-Functional Features of In-Vitro Cell Death Induced by Physical Agents
Current Pharmaceutical Design HIF-1α and Calcium Signaling as Targets for Treatment of Prostate Cancer by Cardiac Glycosides
Current Cancer Drug Targets Mouse Induced Glioma-Initiating Cell Models and Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry The Mechanism of Memory Impairment Induced by Aβ Chronic Administration Involves Imbalance between Cytokines and Neurotrophins in the Rat Hippocampus
Current Alzheimer Research Pharmacological Modulation of Reactive Oxygen Species in Cancer Treatment
Current Drug Targets Reactivity-Based Drug Discovery Using Vitamin B6-Derived Pharmacophores
Mini-Reviews in Medicinal Chemistry Are Retinoids a Promise for Alzheimer’s Disease Management?
Current Medicinal Chemistry Melatonin as Antioxidant Under Pathological Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Antibody-Targeted Immunoliposomes for Cancer Treatment
Mini-Reviews in Medicinal Chemistry Synthesis and Biological Evaluation of Naloxone and Naltrexone-Derived Hybrid Opioids
Medicinal Chemistry Targeting Calcium Channels to Block Tumor Vascularization
Recent Patents on Anti-Cancer Drug Discovery Radionuclide Antibody-Conjugates, a Targeted Therapy Towards Cancer
Current Radiopharmaceuticals Patented Small Molecules Used for Reprogramming
Recent Patents on Regenerative Medicine Vasoactive Intestinal Peptide Receptors: A Molecular Target in Breast and Lung Cancer
Current Pharmaceutical Design Therapeutic Application of Histone Deacetylase Inhibitors for Stroke
Central Nervous System Agents in Medicinal Chemistry Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Serum Testosterone and Cognitive Function in Ageing Male: Updating the Evidence
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy
Current Pharmaceutical Design The PI3K-AKt-mTOR Pathway and New Tools to Prevent Acquired Hormone Resistance in Breast Cancer
Current Pharmaceutical Biotechnology Cancer Therapy: Targeting Mitochondria and other Sub-cellular Organelles
Current Pharmaceutical Design